Predicting Disease Progression in CLL Patients on Ibrutinib

In this interview we discuss prognostic models that may be able to predict disease progression in patients with chronic lymphocytic leukemia treated with the targeted agent ibrutinib.

Source: CancerNetwork - December 3, 2016 Category: Cancer & Oncology Authors: Inhye E. Ahn, MD Tags: Conferences/ASH 2016 Hematologic Malignancies Leukemia & Lymphoma Source Type: news